From: Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
Dose-Escalation Schedule
Dose Level
ALT-803
M7824
Level − 1
8 mcg/kg s.c.
1200 mg i.v.
Level 1
10 mcg/kg s.c.
Level 2
15 mcg/kg s.c.